Literature DB >> 22169593

Circulating biomarkers and abdominal aortic aneurysm size.

Femke A M V I Hellenthal1, Bianca Pulinx, Rob J Th J Welten, Joep A W Teijink, Marja P van Dieijen-Visser, Will K W H Wodzig, Geert Willem H Schurink.   

Abstract

BACKGROUND: Abdominal aortic aneurysm (AAA) is a degenerative disease of the abdominal aorta leading to progressive dilatation, intra-luminal thrombus (ILT) formation, and rupture. Understanding the natural history of AAA is essential, because different processes and, therefore, different biomarkers, could be involved at each stage of disease progression. The purpose of the present study was to investigate the relationship between systemic expression of biomarkers of inflammation and extracellular matrix remodeling and aneurysm size in AAA patients. METHODS AND
RESULTS: All consecutive patients admitted to the (out-) patient clinic of the surgical department of two large community centers were prospectively included. Patients were divided into three groups based on their aneurysm diameter: small (30-44 mm; n = 59), medium-sized (45-54 mm; n = 64) or large (≥ 55 mm; n = 95) AAA. Linear regression modeling showed that age and serum hsCRP concentration were positively associated, whereas serum HDL and IgG concentrations were negatively associated with aneurysm size. This regression model was corrected for possible bias due to statin use and center of inclusion; and also indicated that in general men have larger aneurysms compared with women.
CONCLUSIONS: Different aneurysm sizes showed different expression pattern of HDL, IgG, and hsCRP. These biomarkers may be useful in predicting AAA progression.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22169593     DOI: 10.1016/j.jss.2011.09.040

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  Plasma biomarkers for distinguishing etiologic subtypes of thoracic aortic aneurysm disease.

Authors:  John S Ikonomidis; Charlotte R Ivey; Jason B Wheeler; Adam W Akerman; Allison Rice; Risha K Patel; Robert E Stroud; Asad A Shah; Chad G Hughes; Giovanni Ferrari; Rupak Mukherjee; Jeffrey A Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2013-01-11       Impact factor: 5.209

2.  Prediction of abdominal aortic aneurysm calcification by means of variation of high-sensitivity C-reactive protein.

Authors:  Emirena Garrafa; Alessio Giacomelli; Marco Ravanelli; Patrizia Dell'Era; Michele Peroni; Camilla Zanotti; Luigi Caimi; Stefano Bonardelli
Journal:  JRSM Cardiovasc Dis       Date:  2016-12-06

3.  A Simple Blood Test, Such as Complete Blood Count, Can Predict Calcification Grade of Abdominal Aortic Aneurysm.

Authors:  Marika Vezzoli; Stefano Bonardelli; Michele Peroni; Marco Ravanelli; Emirena Garrafa
Journal:  Int J Vasc Med       Date:  2017-08-30

4.  Dysregulation of microRNA Modulatory Network in Abdominal Aortic Aneurysm.

Authors:  Daniel P Zalewski; Karol P Ruszel; Andrzej Stępniewski; Dariusz Gałkowski; Jacek Bogucki; Łukasz Komsta; Przemysław Kołodziej; Paulina Chmiel; Tomasz Zubilewicz; Marcin Feldo; Janusz Kocki; Anna Bogucka-Kocka
Journal:  J Clin Med       Date:  2020-06-24       Impact factor: 4.241

5.  T Cells Are Dominant Population in Human Abdominal Aortic Aneurysms and Their Infiltration in the Perivascular Tissue Correlates With Disease Severity.

Authors:  Agnieszka Sagan; Tomasz P Mikolajczyk; Wojciech Mrowiecki; Neil MacRitchie; Kevin Daly; Alan Meldrum; Serena Migliarino; Christian Delles; Karol Urbanski; Grzegorz Filip; Boguslaw Kapelak; Pasquale Maffia; Rhian Touyz; Tomasz J Guzik
Journal:  Front Immunol       Date:  2019-09-04       Impact factor: 7.561

6.  IgG Anti-High Density Lipoprotein Antibodies Are Elevated in Abdominal Aortic Aneurysm and Associated with Lipid Profile and Clinical Features.

Authors:  Javier Rodríguez-Carrio; Jes S Lindholt; Marina Canyelles; Diego Martínez-López; Mireia Tondo; Luis M Blanco-Colio; Jean-Baptiste Michel; Joan Carles Escolà-Gil; Ana Suárez; José Luis Martín-Ventura
Journal:  J Clin Med       Date:  2019-12-26       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.